← FDA DRUG APPROVALS

FDA ANDA · ANDA209855

GABAPENTIN

Sponsor: IPCA LABS LTD

APPLICATION
ANDA209855
TYPE
ANDA
ORIGINAL APPROVAL
2024-05-29
LATEST ACTION
2026-02-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

GABAPENTINDiscontinued
GABAPENTIN 600MG · TABLET · ORAL
GABAPENTINDiscontinued
GABAPENTIN 800MG · TABLET · ORAL

Approval history

2026-02-24Labeling · Supplement 2 · standardAP
2024-10-11Labeling · Supplement 1 · standardAP
2024-05-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →